What is known on this topic

Bypassing options for patients with hemophilia and inhibitors are currently limited to Factor VIIa based products, and those are suboptimal for prevention and treatment of bleeding. “Factor Va activity augmentation” was introduced recently as a new modality to correct bleeding in severe bleeding situations. SuperFVa, a molecule engineered with near complete resistance against Activated Protein C and high specific activity by interdomain disulfide linkage, has been identified as a lead candidate for this approach. SuperFVa demonstrated superior procoagulant and prohemostatic properties in hemophilic plasma and in animal models of hemophilic and traumatic bleeding.

What the paper adds

The paper describes the procoagulant, clot stabilizing and prohemostatic effects of superFVa in hemophilia complicated by inhibitors in vitro and in vivo. The combination of superFVa and rhFVIIa demonstrated synergistic effects in vitro, and improved hemostasis in hemophilia mice and wild-type mice with inhibitors significantly. “Factor Va activity augmentation” with superFVa was found to be an efficacious strategy to improve coagulation and hemostasis in hemophilia with inhibitors and deserves consideration as a new bypassing strategy